Grifols (GRFS) Non-Current Debt (2009 - 2025)
Grifols' (GRFS) quarterly Non-Current Debt came in at $10.6 billion in Q4 2025, up 4.34% YoY from $10.1 billion in Q4 2024, and up 4.34% on a QoQ basis from $10.1 billion in Q4 2024.
Grifols (GRFS) Non-Current Debt (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Non-Current Debt data on file, last reported at $10.6 billion in Q4 2025.
- Quarterly Non-Current Debt rose 4.34% year-over-year to $10.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.6 billion (up 4.34% YoY) and the FY2025 annual result came in at $10.6 billion, up 4.34% from the prior year.
- Non-Current Debt climbed to $10.6 billion in Q4 2025, from $10.1 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $10.8 billion in Q4 2023 to a low of $959.6 million in Q4 2021.
- A 5-year average of $8.6 billion and a median of $10.3 billion in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2021 — Non-Current Debt slumped 87.81% — and 2022, when it surged 971.09%.
- Tracing GRFS's Non-Current Debt over 5 years: stood at $959.6 million in 2021, then surged by 971.09% to $10.3 billion in 2022, then advanced by 5.03% to $10.8 billion in 2023, then fell by 6.05% to $10.1 billion in 2024, then rose by 4.34% to $10.6 billion in 2025.
- The last three Non-Current Debt figures came in at $10.6 billion (Q4 2025), $10.1 billion (Q4 2024), and $10.8 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.91 Bn | 632.15 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.40 Bn | 462.83 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 375.75 Bn | 368.61 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.13 Bn | 295.44 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 236.26 Bn | 222.27 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 182.12 Bn | 178.95 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.21 Bn | 102.04 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 10.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.58 Bn |
| Dec 31, 2024 | 10.14 Bn |
| Dec 31, 2023 | 10.80 Bn |
| Dec 31, 2022 | 10.28 Bn |
| Dec 31, 2021 | 959.59 Mn |
| Dec 31, 2020 | 7.87 Bn |
| Sep 30, 2020 | 7.86 Bn |
| Mar 31, 2020 | 7.58 Bn |
| Dec 31, 2019 | 66.39 Mn |
| Sep 30, 2019 | 7.68 Bn |
| Dec 31, 2018 | 90.12 Mn |
| Sep 30, 2018 | 7.11 Bn |
| Jun 30, 2018 | 7.19 Bn |
| Mar 31, 2018 | 8.43 Bn |
| Dec 31, 2017 | 27.83 Mn |
| Jun 30, 2017 | 6.64 Bn |
| Dec 31, 2016 | 5.09 Bn |
| Sep 30, 2016 | 5.01 Bn |
| Jun 30, 2016 | 5.10 Bn |
| Mar 31, 2016 | 28.34 Mn |